From guideline approval to market demand, atropine has become the mainstay in the field of myopia prevention and control
Nowadays, myopia prevention and control has become a real problem that urgently needs to be solved, and atropine has shown great market potential in this field, becoming an important choice for the solution.
Statistics from the National Health Commission show that the number of myopic people in the country has reached about million. Especially among young people, the prevalence of high myopia greater than degrees latvia phone number list is about % to %, which is to times the international level. Looking further, the overall myopia rate among children and adolescents is .%, including .% for primary school students, .% for junior high school students, and .% for high school students. These data all indicate that there is huge potential and demand in the myopia prevention and control market.
Atropine eye drops have become a highly competitive product with its unique advantages and wide market recognition.
On the one hand, lowconcentration atropine eye drops were included in the "Guidelines for Myopia Prevention and Treatment" for the first time, and their effectiveness was recognized at the national level. The "Guidelines for Myopia Prevention and Treatment Edition" clearly states that lowconcentration atropine eye drops are drugs that have been proven by evidencebased medicine to effectively delay the progression of myopia.